Can denosumab be a substitute, competitor, or complement to bisphosphonates?

Osteoblasts, originating from mesenchymal cells, make the receptor activator of the nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) in order to control differentiation of activated osteoclasts, originating from hematopoietic stem cells. When the RANKL binds to the RANK of the pre-ost...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Su Young, Ok, Hwoe Gyeong, Birkenmaier, Christof, Kim, Kyung Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Pain Society 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392661/
https://www.ncbi.nlm.nih.gov/pubmed/28416991
http://dx.doi.org/10.3344/kjp.2017.30.2.86

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392661/
https://www.ncbi.nlm.nih.gov/pubmed/28416991
http://dx.doi.org/10.3344/kjp.2017.30.2.86

Ejemplares similares